Thanks bear. After I posted I did realize it had to be RRR. Seems like this is the norm for publishing and I assume the absolute risk reductions are available in the scientific papers.

Regarding the power of BoM stat design perhaps if we get a positive FA we still may see the need to expand the sample size for final results. I'm thinking with the FA extended to a larger sample it may be a probability issue and this, to me, hints of a larger trial.

Your final point "it's (apabetalone's) many cardio protective actions" seems such a central set of benefits and it's potential reach to Alzheimer's, CKD, retinal, Fabry, etc creates great hope for me.

Therefore I think it is important that as RVX works through this trial they also get moving on other trials for this drug if for no other reason than insurance and to enhance the opportunity for suitors, licensees or other types of partners to get involved.

GLTA

Toinv